Polaryx Therapeutics Common Stock Overview

Polaryx Therapeutics Common Stock Research & Development

Research & Development expenses for PLYX.

Quarterly R&D Expenses

$679000.00

↓ 85.6% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$2.23M

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin